2.45
+0.06(+2.51%)
Currency In USD
Previous Close | 2.39 |
Open | 2.4 |
Day High | 2.47 |
Day Low | 2.36 |
52-Week High | 19.1 |
52-Week Low | 1.6 |
Volume | 425,232 |
Average Volume | 724,898 |
Market Cap | 181.42M |
PE | -2.01 |
EPS | -1.22 |
Moving Average 50 Days | 2.37 |
Moving Average 200 Days | 7.58 |
Change | 0.06 |
If you invested $1000 in Perspective Therapeutics, Inc. (CATX) 10 years ago, it would be worth $143.27 as of April 29, 2025 at a share price of $2.45. Whereas If you bought $1000 worth of Perspective Therapeutics, Inc. (CATX) shares 5 years ago, it would be worth $360.29 as of April 29, 2025 at a share price of $2.45.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Perspective Therapeutics Announces Acceptance of VMT-α-NET and VMT01 Data for Presentation at the 2025 ASCO Annual Meeting
GlobeNewswire Inc.
Apr 23, 2025 4:25 PM GMT
SEATTLE, April 23, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced that da
Perspective Therapeutics to Provide Business Highlights and Report First Quarter 2025 Financial Results
GlobeNewswire Inc.
Apr 17, 2025 11:00 AM GMT
SEATTLE, April 17, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced that i
Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 Monotherapy at 1.5 mCi in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma
GlobeNewswire Inc.
Apr 11, 2025 11:00 AM GMT
SEATTLE, April 11, 2025 (GLOBE NEWSWIRE) -- Perspective, Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, announced today that